Last reviewed · How we verify
Rivastigmine, memantine
Rivastigmine, memantine is a Cholinesterase inhibitor and NMDA receptor antagonist combination Small molecule drug developed by Novartis. It is currently FDA-approved for Moderate to severe Alzheimer's disease.
This combination drug enhances acetylcholine levels in the brain while blocking NMDA receptor overactivity to slow cognitive decline in Alzheimer's disease.
Rivastigmine is a small molecule used to treat conditions such as dementia and Alzheimer's disease. Memantine is also a small molecule, specifically used to treat conditions including dementia and Alzheimer's disease, as indicated by ClinicalTrials.gov.
At a glance
| Generic name | Rivastigmine, memantine |
|---|---|
| Sponsor | Novartis |
| Drug class | Cholinesterase inhibitor and NMDA receptor antagonist combination |
| Target | Acetylcholinesterase and NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Rivastigmine is a cholinesterase inhibitor that prevents the breakdown of acetylcholine, increasing its availability in the brain to improve cognitive function. Memantine is an NMDA receptor antagonist that reduces excitotoxicity from excess glutamate signaling. Together, they address two different pathological mechanisms in Alzheimer's disease through complementary actions.
Approved indications
- Moderate to severe Alzheimer's disease
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Dizziness
- Headache
- Fatigue
- Syncope
Key clinical trials
- Masitinib in Patients With Mild Alzheimer's Disease (PHASE3)
- Quality Improvement and Practice Based Research in Neurology Using the EMR (PHASE4)
- Masitinib in Patients With Mild to Moderate Alzheimer's Disease (PHASE3)
- Withdrawal of Antidementia Drugs in Advanced Dementia (WADAD) (NA)
- The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease (NA)
- Quality of the Management of Diabetes in Elderly People With Dementia in France
- Deep Brain Stimulation for Alzheimer's Disease (NA)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivastigmine, memantine CI brief — competitive landscape report
- Rivastigmine, memantine updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Rivastigmine, memantine
What is Rivastigmine, memantine?
How does Rivastigmine, memantine work?
What is Rivastigmine, memantine used for?
Who makes Rivastigmine, memantine?
What drug class is Rivastigmine, memantine in?
What development phase is Rivastigmine, memantine in?
What are the side effects of Rivastigmine, memantine?
What does Rivastigmine, memantine target?
Related
- Drug class: All Cholinesterase inhibitor and NMDA receptor antagonist combination drugs
- Target: All drugs targeting Acetylcholinesterase and NMDA receptor
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Moderate to severe Alzheimer's disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing